MDM2 and prostate carcinoma: We now show that Mdm2 C305F mutation results in decreased prostate size and, unlike the situation in Myc-induced B cell lymphomagenesis [11], slows the progression of prostate tumorigenesis induced by inactivation of pRb family proteins in the well-characterized APT121 mouse model of prostate cancer [32].